

LIST OF TABLES

1.1 List of Tables

- Table 1: McDonald Criteria, Multiple Sclerosis, 2013
- Table 2: Expanded Disability Status Scale, Multiple Sclerosis, 2013
- Table 3: Multiple Sclerosis, Global, Market Forecast, (\$bn), 2012–2019
- Table 4: Multiple Sclerosis, US, Market Forecast, (\$bn), 2012–2019
- Table 5: Multiple Sclerosis, UK, Market Forecast, (\$bn), 2012–2019
- Table 6: Multiple Sclerosis, France, Market Forecast, (\$bn), 2012–2019
- Table 7: Multiple Sclerosis, Germany, Market Forecast, (\$bn), 2012–2019
- Table 8: Multiple Sclerosis, Italy, Market Forecast, (\$bn), 2012–2019
- Table 9: Multiple Sclerosis, Spain, Market Forecast, (\$bn), 2012–2019
- Table 10: Multiple Sclerosis, Japan, Market Forecast, (\$bn), 2012–2019

1.2 List of Figures

- Figure 1: Treatment Algorithm, Global, Multiple Sclerosis, 2013
- Figure 2: Multiple Sclerosis, Marketed Products Heat Map
- Figure 3: Overall Pipeline for Multiple Sclerosis
- Figure 4: Routes of Administration in the Pipeline
- Figure 5: Molecular Targets of Pipeline Molecules
- Figure 6: Molecular Targets in MS Pipeline by Phase of Development
- Figure 7: Failure Rate of MS Clinical Trials, 2006–2013
- Figure 8: Reasons for Clinical Trial Failure, 2006–2013
- Figure 9: Clinical Trial Size by Product and Phase, 2006–2013
- Figure 10: Clinical Trial Duration by Phase and Molecule Type, 2006–2013
- Figure 11: Multiple Sclerosis, Pipeline Product Heat Map
- Figure 12: Multiple Sclerosis, Marketed Product Heat Map, 2012–2019
- Figure 13: Multiple Sclerosis Market, Global, Patient Volumes ('000) and Market Size (\$bn), 2012–2019
- Figure 14: Multiple Sclerosis Market, US, Patient Volumes ('000), Annual Cost of Treatment (\$) and Market Size (\$bn), 2012–2019
- Figure 15: Multiple Sclerosis Market, EU5, Patient Population ('000), 2012–2019
- Figure 16: Multiple Sclerosis Market, EU5, Annual Cost of Treatment (\$), 2012–2019
- Figure 17: Multiple Sclerosis Market, EU5, Market Size (\$bn), 2013–2019
- Figure 18: Multiple Sclerosis Market, Japan, Patient Volume ('000), Annual Cost of Treatment (\$) and Market Size (\$bn), 2013–2019
- Figure 19: Multiple Sclerosis, Co-development Deals by Geography, Value and Year, 2006–2013
- Figure 20: Multiple Sclerosis, Co-Development Deal Frequency by Phase and Molecule Type 2006–2013
- Figure 21: Multiple Sclerosis, Licensing Deals by Geography, Value and Year, 2006–2013
- Figure 22: Multiple Sclerosis, Licensing Deal frequency by Phase and Molecule Type, 2006–2013

Figure 23: Multiple Sclerosis, Licensing Deal Value by Molecule Type and Mechanism of Action, 2006–2013

Figure 24: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Discovery)

Figure 25: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Pre-Clinical)-I

Figure 26: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Pre-Clinical)-II

Figure 27: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Pre-Clinical)-III

Figure 28: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Phase I) -I

Figure 29: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Phase I) -II

Figure 30: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Phase II) - I

Figure 31: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Phase II) - II

Figure 32: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Phase III)

Figure 33: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Pre-Registration)

Figure 34: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Undisclosed)

Figure 35: Multiple Sclerosis Market, Global, GBI Research Market Sizing Model